183 related articles for article (PubMed ID: 25245038)
1. Hyperammonemia secondary to asparaginase: A case series.
Nussbaum V; Lubcke N; Findlay R
J Oncol Pharm Pract; 2016 Feb; 22(1):161-4. PubMed ID: 25245038
[TBL] [Abstract][Full Text] [Related]
2. Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group.
Rau RE; Dreyer Z; Choi MR; Liang W; Skowronski R; Allamneni KP; Devidas M; Raetz EA; Adamson PC; Blaney SM; Loh ML; Hunger SP
Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29090524
[TBL] [Abstract][Full Text] [Related]
3. Pegaspargase-induced pancreatitis.
Alvarez OA; Zimmerman G
Med Pediatr Oncol; 2000 Mar; 34(3):200-5. PubMed ID: 10696127
[TBL] [Abstract][Full Text] [Related]
4. Transient hyperammonemia due to L-asparaginase therapy in children with acute lymphoblastic leukemia or non-Hodgkin lymphoma.
Jörck C; Kiess W; Weigel JF; Mütze U; Bierbach U; Beblo S
Pediatr Hematol Oncol; 2011 Feb; 28(1):3-9. PubMed ID: 20615069
[TBL] [Abstract][Full Text] [Related]
5. The use of Erwinia asparaginase for adult patients with acute lymphoblastic leukemia after pegaspargase intolerance.
Horvat TZ; Pecoraro JJ; Daley RJ; Buie LW; King AC; Rampal RK; Tallman MS; Park JH; Douer D
Leuk Res; 2016 Nov; 50():17-20. PubMed ID: 27631159
[TBL] [Abstract][Full Text] [Related]
6. Treatment and outcomes of symptomatic hyperammonemia following asparaginase therapy in children with acute lymphoblastic leukemia.
Lee A; Eldem I; Altintas B; Nguyen H; Willis D; Langley R; Shinawi M
Mol Genet Metab; 2023 Jul; 139(3):107627. PubMed ID: 37327713
[TBL] [Abstract][Full Text] [Related]
7. [Activity of Erwinia-asparaginase after anaphylactic reaction to Peg-asparaginase].
Viña Romero MM; García Gil S; Nazco Casariego GJ; Merino Alonso J; Gutiérrez Nicolás F
An Pediatr (Engl Ed); 2019 Mar; 90(3):187-188. PubMed ID: 29705180
[No Abstract] [Full Text] [Related]
8. Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children's Oncology Group.
Salzer WL; Asselin B; Supko JG; Devidas M; Kaiser NA; Plourde P; Winick NJ; Reaman GH; Raetz E; Carroll WL; Hunger SP
Blood; 2013 Jul; 122(4):507-14. PubMed ID: 23741010
[TBL] [Abstract][Full Text] [Related]
9. Symptomatic Hyperammonemia With Erwinia chrysanthemi-derived Asparaginase in Pediatric Leukemia Patients.
Gossai N; Richards M; Boman L; Messinger Y; Gernbacher S; Perkins J; Bostrom B
J Pediatr Hematol Oncol; 2018 May; 40(4):312-315. PubMed ID: 29334534
[TBL] [Abstract][Full Text] [Related]
10. PEGylated
Verma A; Chen K; Bender C; Gorney N; Leonard W; Barnette P
Pediatr Hematol Oncol; 2019 Aug; 36(5):277-286. PubMed ID: 31296092
[TBL] [Abstract][Full Text] [Related]
11. Pegaspargase: A Review in Acute Lymphoblastic Leukaemia.
Heo YA; Syed YY; Keam SJ
Drugs; 2019 May; 79(7):767-777. PubMed ID: 31030380
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy observation of polyethylene glycol conjugated asparaginase for induction treatment of children with newly diagnosed acute lymphoblastic leukemia].
Liu F; Wan Y; Chang L; Guo Y; Yang W; Wang S; Chen X; Liu T; Ruan M; Zhang L; Liu X; Zou Y; Chen Y; Zhu X
Zhonghua Er Ke Za Zhi; 2014 Mar; 52(3):215-7. PubMed ID: 24824393
[TBL] [Abstract][Full Text] [Related]
13. Pegaspargase-induced hypertriglyceridemia in a patient with acute lymphoblastic leukemia.
Lau KM; Saunders IM; Goodman A
J Oncol Pharm Pract; 2020 Jan; 26(1):193-199. PubMed ID: 30823860
[TBL] [Abstract][Full Text] [Related]
14. Symptomatic hyperammonemia secondary to recombinant Erwinia asparaginase.
Martin CE; Kohorst MA; Ferdjallah A; Kalmes JL; Johnson HM; Galardy PJ; Khan SP; Kuhn AK
Pediatr Blood Cancer; 2023 May; 70(5):e30208. PubMed ID: 36633209
[No Abstract] [Full Text] [Related]
15. Desensitization using pegaspargase in the era of commercially available Erwinia: A single-institution report on efficacy, cost, and resource utilization.
Feldman K; Aaronson K; Gu T; Ige K; Southworth E; Sanchez L; Stieglitz E
Pediatr Blood Cancer; 2024 Apr; 71(4):e30891. PubMed ID: 38311802
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of early response to a single dose of asparaginase in childhood acute lymphoblastic leukemia.
Asselin BL; Kreissman S; Coppola DJ; Bernal SD; Leavitt PR; Gelber RD; Sallan SE; Cohen HJ
J Pediatr Hematol Oncol; 1999; 21(1):6-12. PubMed ID: 10029805
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamics of cerebrospinal fluid asparagine after asparaginase.
Panetta JC; Liu Y; Bottiglieri T; Arning E; Cheng C; Karol SE; Yang JJ; Zhou Y; Inaba H; Pui CH; Jeha S; Relling MV
Cancer Chemother Pharmacol; 2021 Oct; 88(4):655-664. PubMed ID: 34170389
[TBL] [Abstract][Full Text] [Related]
18. [Molecular basis of hyperammonemia secondary to asparaginase: from therapeutic efficacity to toxicity].
Gallin M; Damaj L; Gandemer V; Bendavid C; Moreau C
Ann Biol Clin (Paris); 2023 Oct; 81(4):365-377. PubMed ID: 37864442
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients.
Wang B; Relling MV; Storm MC; Woo MH; Ribeiro R; Pui CH; Hak LJ
Leukemia; 2003 Aug; 17(8):1583-8. PubMed ID: 12886246
[TBL] [Abstract][Full Text] [Related]
20. Individualized Asparaginase Dosing in Childhood Acute Lymphoblastic Leukemia.
Kloos RQH; Pieters R; Jumelet FMV; de Groot-Kruseman HA; van den Bos C; van der Sluis IM
J Clin Oncol; 2020 Mar; 38(7):715-724. PubMed ID: 31922920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
